Sarepta Therapeutics said on Tuesday a 16-year-old boy has died due to acute liver failure, months after he received the company's U.S-approved gene therapy for a rare muscular dystrophy. The patient underwent treatment in December with Sarepta's Elevidys,

Sarepta Therapeutics said early Tuesday that a patient had died after receiving its gene therapy Elevidys, which treats the rare genetic condition Duchenne muscular dystrophy. A young man with Duchenne muscular dystrophy had died from acute liver failure after being treated with the medicine,